Table 3:
Cox regression on results on mortality (Model 1) and cardiovascular events (Model 2).
| Model 1: | Model 2: | |||
|---|---|---|---|---|
| N of patients = 368 | N of patients = 368 | |||
| N of deaths = 220 | N of cardiovascular events = 192 | |||
| HR (95%CI) | P-value | HR (95%CI) | P-value | |
| LAA occlusion vs warfarin | 0.60 (0.38–0.94) | 0.027 | 0.38 (0.23–0.62) | <0.001 |
| LAA occlusion vs No-OAT | 0.52 (0.34–0.78) | 0.002 | 0.45 (0.29–0.7) | <0.001 |
| Gender (males) | 1.06 (0.78–1.45) | 0.687 | 0.74 (0.53–1.03) | 0.071 |
| Age (yrs) | 1.02 (1.00–1.04) | 0.013 | 0.97 (0.95–0.99) | 0.004 |
| Dialytic age (yrs) | 1.01 (0.99–1.03) | 0.267 | 1.03 (1–1.05) | 0.022 |
| CHA2DS2VASc (for each point) | 1.23 (1.08–1.4) | 0.002 | 1.1 (0.95–1.29) | 0.197 |
| HASBLED (for each point) | 0.87 (0.69–1.1) | 0.245 | 1.4 (1.09–1.78) | 0.008 |
| Persistent vs paroxysmal AF | 1.02 (0.69–1.5) | 0.917 | 0.86 (0.58–1.27) | 0.451 |
| Permanent vs paroxysmal AF | 1.60 (1.09–2.33) | 0.016 | 0.88 (0.58–1.32) | 0.526 |
| Dyslipidemia | 0.94 (0.69–1.26) | 0.663 | 1.11 (0.81–1.54) | 0.510 |
| Peripheral artery disease | 0.96 (0.69–1.34) | 0.807 | 1.67 (1.15–2.43) | 0.007 |
| Previous major bleedings | 1.37 (0.93–2.02) | 0.108 | 1.43 (0.97–2.11) | 0.069 |
| Antiplatelet therapy | 1.43 (1.02–2.00) | 0.038 | 0.69 (0.48–0.98) | 0.038 |
AF, atrial fibrillation; LAA, left atrial appendage; OAT, oral anticoagulant therapy.